Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with diagnosed rheumatoid arthritis (RA) for at least 6 months prior who is otherwise judged to be in general good health and who is currently taking nonsteroidal anti-inflammatory drugs (NSAIDS) to treat his/her RA symptoms~* Patient will need to stop taking these medications in order to participate, but can continue taking his/her other anti-rheumatic medications as long as they have been stable for certain periods of time~Exclusion Criteria:~* Patients with a disease or medical condition(s) that could worsen or interfere with the evaluation of the effectiveness of study medication are not allowed to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Period I: 1 (Type: EXPERIMENTAL): etoricoxib
- Period I: 2 (Type: EXPERIMENTAL): etoricoxib
- Period I: 3 (Type: EXPERIMENTAL): etoricoxib
- Period I: 4 (Type: EXPERIMENTAL): etoricoxib
- Period I: 5 (Type: PLACEBO_COMPARATOR): Placebo
- Period II: 1 (Type: EXPERIMENTAL): etoricoxib
- Period II: 2 (Type: ACTIVE_COMPARATOR): diclofenac

Based on this trial design, predict the completion outcome and termination type (if applicable).